MLH1、MSH2和MSH6致病性变异与结直肠腺瘤和肿瘤风险及体细胞突变的关系
该研究联合德国、荷兰和芬兰3项研究数据,纳入2747例MLH1、MSH2或MSH6致病变异的Lynch综合征患者,中位随访7.8年。肿瘤体细胞突变谱因MMR基因而异。
要点
- MSH2变异者10年进展期腺瘤风险高于MLH1变异者(17.8% vs 7.7%)。
- MLH1或MSH2变异者10年结直肠癌风险高于MSH6变异者(11.3%和11.4% vs 4.7%)。
- MSH2变异肿瘤APC突变常见,MLH1变异肿瘤CTNNB1突变常见。
核心结论
- Lynch综合征患者中,MMR基因致病性变异类型与腺瘤和结直肠癌风险及肿瘤体细胞突变相关。
研究设计与样本
- 联合3项研究,纳入2747例MLH1、MSH2或MSH6致病变异的Lynch综合征患者,至少接受2次监测性结肠镜,中位随访7.8年。
- 对48例结直肠肿瘤(MLH1变异16例、MSH2变异29例、MSH6变异3例)进行APC和CTNNB1体细胞突变DNA序列分析。
主要发现
- MSH2变异者10年进展期腺瘤风险为17.8%,MLH1变异者为7.7%(P < .001)。
- MLH1和MSH2变异者10年结直肠癌风险分别为11.3%和11.4%,MSH6变异者为4.7%(MLH1 vs MSH6 P = .001;MSH2 vs MSH6 P = .003)。
- MSH2变异肿瘤中APC体细胞突变占75%,MLH1变异肿瘤中占11%(P = .015)。
- MLH1变异肿瘤中CTNNB1体细胞突变占50%,MSH2变异肿瘤中占7%(P = .002)。
- MSH6变异的3例肿瘤均无CTNNB1突变,但均有APC突变。
临床怎么用
- 若研究结果被证实,监测指南可能根据MMR基因变异类型进行调整。
局限性
- 研究结论需进一步确认后,才可考虑据此调整监测指南。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Lynch syndrome is caused by variants in DNA mismatch repair (MMR) genes and associated with an increased risk of colorectal cancer (CRC). In patients with Lynch syndrome, CRCs can develop via different pathways. We studied associations between Lynch syndrome-associated variants in MMR genes and risks of adenoma and CRC and somatic mutations in APC and CTNNB1 in tumors in an international cohort of patients. METHODS: We combined clinical and molecular data from 3 studies. We obtained clinical data from 2747 patients with Lynch syndrome associated with variants in MLH1, MSH2, or MSH6 from Germany, the Netherlands, and Finland who received at least 2 surveillance colonoscopies and were followed for a median time of 7.8 years for development of adenomas or CRC. We performed DNA sequence analyses of 48 colorectal tumors (from 16 patients with mutations in MLH1, 29 patients with mutations in MSH2, and 3 with mutations in MSH6) for somatic mutations in APC and CTNNB1. RESULTS: Risk of advanced adenoma in 10 years was 17.8% in patients with pathogenic variants in MSH2 vs 7.7% in MLH1 (P < .001). Higher proportions of patients with pathogenic variants in MLH1 or MSH2 developed CRC in 10 years (11.3% and 11.4%) than patients with pathogenic variants in MSH6 (4.7%) (P = .001 and P = .003 for MLH1 and MSH2 vs MSH6, respectively). Somatic mutations in APC were found in 75% of tumors from patients with pathogenic variants in MSH2 vs 11% in MLH1 (P = .015). Somatic mutations in CTNNB1 were found in 50% of tumors from patients with pathogenic variants in MLH1 vs 7% in MSH2 (P = .002). None of the 3 tumors with pathogenic variants in MSH6 had a mutation in CTNNB1, but all had mutations in APC. CONCLUSIONS: In an analysis of clinical and DNA sequence data from patients with Lynch syndrome from 3 countries, we associated pathogenic variants in MMR genes with risk of adenoma and CRC, and somatic mutations in APC and CTNNB1 in colorectal tumors. If these findings are confirmed, surveillance guidelines might be adjusted based on MMR gene variants.
引用
- Engel C, Ahadova A, Seppälä TT, et al. Associations of Pathogenic Variants in MLH1, MSH2, and MSH6 With Risk of Colorectal Adenomas and Tumors and With Somatic Mutations in Patients With Lynch Syndrome. Gastroenterology. 2020. PMID: 31926173. doi:10.1053/j.gastro.2019.12.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。